Journal
DIAGNOSTICS
Volume 11, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/diagnostics11020252
Keywords
pancreatic cancer; biliary tract cancer; targeted therapy; solid tumours; driver mutations; agonist therapy
Categories
Funding
- JSPS KAKENHI [19K07740]
- Grants-in-Aid for Scientific Research [19K07740] Funding Source: KAKEN
Ask authors/readers for more resources
The prognosis of patients with solid tumors has been significantly improved with the development of molecular-targeted drugs and immune checkpoint inhibitors. However, pancreatic cancer and biliary tract cancer still have lower survival rates compared to other carcinomas. The Cancer Genome Atlas (TCGA) project has identified various driver mutations, leading to basket trials targeting these mutations regardless of the primary organ.
The prognosis of patients with solid tumours has remarkably improved with the development of molecular-targeted drugs and immune checkpoint inhibitors. However, the improvements in the prognosis of pancreatic cancer and biliary tract cancer is delayed compared to other carcinomas, and the 5-year survival rates of distal-stage disease are approximately 10 and 20%, respectively. However, a comprehensive analysis of tumour cells using The Cancer Genome Atlas (TCGA) project has led to the identification of various driver mutations. Evidently, few mutations exist across organs, and basket trials targeting driver mutations regardless of the primary organ are being actively conducted. Such basket trials not only focus on the gate keeper-type oncogene mutations, such as HER2 and BRAF, but also focus on the caretaker-type tumour suppressor genes, such as BRCA1/2, mismatch repair-related genes, which cause hereditary cancer syndrome. As oncogene panel testing is a vital approach in routine practice, clinicians should devise a strategy for improved understanding of the cancer genome. Here, the gene mutation profiles of pancreatic cancer and biliary tract cancer have been outlined and the current status of tumour-agnostic therapy in these cancers has been reported.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available